Loading...

We've got a brand new version of Simply Wall St! Try it out

Choom Holdings

CNSX:CHOO
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CHOO
CNSX
CA$73M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Choom Holdings Inc., through its subsidiary, Medi-Can Health Solutions Ltd, engages in cultivating and selling cannabis for medical purposes and related products. The last earnings update was 114 days ago. More info.


Add to Portfolio Compare Print
  • Choom Holdings has significant price volatility in the past 3 months.
CHOO Share Price and Events
7 Day Returns
-3.8%
CNSX:CHOO
-4.8%
CA Pharmaceuticals
1%
CA Market
1 Year Returns
-70%
CNSX:CHOO
-46.2%
CA Pharmaceuticals
-0.4%
CA Market
CHOO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Choom Holdings (CHOO) -3.8% -6.3% -23.5% -70% 476.9% 1150%
CA Pharmaceuticals -4.8% -4.3% -23.8% -46.2% 224.8% 297.6%
CA Market 1% 3.7% 1.3% -0.4% 8.1% 5.4%
1 Year Return vs Industry and Market
  • CHOO underperformed the Pharmaceuticals industry which returned -46.2% over the past year.
  • CHOO underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
CHOO
Industry
5yr Volatility vs Market

Value

 Is Choom Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Choom Holdings. This is due to cash flow or dividend data being unavailable. The share price is CA$0.375.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Choom Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Choom Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CHOO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.08
CNSX:CHOO Share Price ** CNSX (2019-09-20) in CAD CA$0.38
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.46x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Choom Holdings.

CNSX:CHOO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CHOO Share Price ÷ EPS (both in CAD)

= 0.38 ÷ -0.08

-4.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Choom Holdings is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Choom Holdings is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Choom Holdings's expected growth come at a high price?
Raw Data
CNSX:CHOO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.01x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Choom Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Choom Holdings's assets?
Raw Data
CNSX:CHOO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.09
CNSX:CHOO Share Price * CNSX (2019-09-20) in CAD CA$0.38
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.27x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.44x
CNSX:CHOO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CHOO Share Price ÷ Book Value per Share (both in CAD)

= 0.38 ÷ 0.09

3.96x

* Primary Listing of Choom Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Choom Holdings is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Choom Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Choom Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Choom Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Choom Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.1%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Choom Holdings expected to grow at an attractive rate?
  • Unable to compare Choom Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Choom Holdings's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Choom Holdings's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:CHOO Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.1%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CHOO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CHOO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 -10 -14
2018-12-31 -13 -11
2018-09-30 -7 -9
2018-06-30 -5 -7
2018-03-31 -8 -3
2017-12-31 -1 -2
2017-09-30 0 -1
2017-06-30 0 -1
2017-03-31 0 0
2016-12-31 0 -1
2016-09-30 0 -1
2016-06-30 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Choom Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Choom Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CHOO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Choom Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CHOO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.08
2018-12-31 -0.08
2018-09-30 -0.08
2018-06-30 -0.07
2018-03-31 -0.04
2017-12-31 -0.03
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Choom Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CHOO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Choom Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Choom Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Choom Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Choom Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Choom Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Choom Holdings's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Choom Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Choom Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Choom Holdings's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Choom Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Choom Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CHOO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -13.88 13.09 0.17
2018-12-31 -10.85 10.32 0.16
2018-09-30 -8.99 8.46 0.16
2018-06-30 -6.58 6.03 0.17
2018-03-31 -3.17 2.02
2017-12-31 -2.04 1.17 0.01
2017-09-30 -0.76 0.37 0.01
2017-06-30 -0.69 0.31
2017-03-31 -0.49 0.29
2016-12-31 -0.53 0.28
2016-09-30 -0.62 0.37
2016-06-30 -0.63 0.38
2016-03-31 -1.03 0.43
2015-12-31 -1.04 0.41
2015-09-30 -1.06 0.40
2015-06-30 -1.05 0.37
2015-03-31 -1.23 0.20
2014-12-31 -1.29 0.29
2014-09-30 -1.34 0.36
2014-06-30 -1.41 0.46
2014-03-31 -1.08 0.66
2013-12-31 -1.36 0.92
2013-09-30 -1.44 1.00
2013-06-30 -1.56 1.11
2013-03-31 -1.61 1.45
2012-12-31 -1.99 1.85
2012-09-30 -2.06 1.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Choom Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Choom Holdings has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Choom Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Choom Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Choom Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Choom Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Choom Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Choom Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Choom Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Choom Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Choom Holdings Company Filings, last reported 5 months ago.

CNSX:CHOO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 17.95 11.84 9.93
2018-12-31 17.60 11.57 17.44
2018-09-30 97.74 0.25 6.75
2018-06-30 99.59 0.25 9.39
2018-03-31 12.56 2.75 3.05
2017-12-31 3.64 2.80 1.06
2017-09-30 0.34 0.00 0.48
2017-06-30 0.05 0.00 0.12
2017-03-31 0.59 0.00 0.17
2016-12-31 0.18 0.00 0.03
2016-09-30 0.17 0.00 0.02
2016-06-30 -0.12 0.00 0.02
2016-03-31 -0.11 0.00 0.07
2015-12-31 -0.02 0.00 0.04
2015-09-30 0.05 0.00 0.05
2015-06-30 0.14 0.00 0.05
2015-03-31 0.91 0.00 0.03
2014-12-31 1.00 0.00 0.03
2014-09-30 1.06 0.00 0.04
2014-06-30 1.15 0.00 0.05
2014-03-31 2.08 0.00 0.18
2013-12-31 1.78 0.00 0.03
2013-09-30 1.93 0.00 0.13
2013-06-30 2.01 0.00 0.29
2013-03-31 2.59 0.00 0.49
2012-12-31 2.78 0.00 0.76
2012-09-30 2.76 0.00 1.18
  • Choom Holdings's level of debt (66%) compared to net worth is high (greater than 40%).
  • Unable to establish if Choom Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Choom Holdings has less than a year of cash runway based on current free cash flow.
  • Choom Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 120.8% each year.
X
Financial health checks
We assess Choom Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Choom Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Choom Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Choom Holdings dividends.
If you bought CA$2,000 of Choom Holdings shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Choom Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Choom Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CHOO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Choom Holdings has not reported any payouts.
  • Unable to verify if Choom Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Choom Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Choom Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Choom Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Choom Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Choom Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Choom Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Bogart
COMPENSATION CA$130,000
AGE 48
TENURE AS CEO 9.1 years
CEO Bio

Mr. Christopher Bogart, also known as Chris, has been the Chief Executive Officer of Standard Graphite Corporation (now Choom Holdings Inc.) since August 3, 2010 and served as President since August 3, 2010 until August 26, 2019 . Mr. Bogart was the Co-founder of InMed Pharmaceuticals Inc. and served as its Senior Vice President of Corporate Strategy and Investor Relations since August 2015 until July 13, 2017. Mr. Bogart served as Interim Chief Executive Officer of InMed Pharmaceuticals Inc. since May 4, 2016 until June 16, 2016. Mr. Bogart served as Senior Vice President of Corporate Strategy and Investor Relations at InMed Pharmaceuticals Inc. until May 5, 2016. He serves as the President of Metals Management Corp. He is a Beneficial Owner at Orocan Resource Corp. He served as Vice President of Corporate Development at Corex Gold Corp. since August 2009. He served as the President of Rain City Capital from May 2001 to August 2003. Mr. Bogart has been involved in the junior resource sector for over 10 years. He provides strategic consulting, financing and corporate development services to the resource industry. He has been with the mining industry as a Self-Employed Consultant since August 2003. He served as Director of InMed Pharmaceuticals Inc. from May 4, 2016 to June 16, 2016. He has been a Director of Choom Holdings since 2006. Mr. Bogart attended Langara College and UBC.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Choom Holdings management team in years:

1.2
Average Tenure
56
Average Age
  • The average tenure for the Choom Holdings management team is less than 2 years, this suggests a new team.
Management Team

Chris Bogart

TITLE
CEO & Director
COMPENSATION
CA$130K
AGE
48
TENURE
9.1 yrs

Terese Gieselman

TITLE
CFO & Secretary
COMPENSATION
CA$48K
AGE
56

Michael Forbes

TITLE
COO & Director
TENURE
1.2 yrs

Corey Gillon

TITLE
President
TENURE
0.1 yrs

Paddy Downey

TITLE
AGE
59

Chris Gagan

TITLE
Senior Vice President of Branding & Marketing
TENURE
1.6 yrs

Aussie Jiwani

TITLE
Director of Sales
TENURE
1.2 yrs

Daphne Kao

TITLE
Vice President of People & Culture

Lamar Hanna

TITLE
Senior Vice President of Retail
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Choom Holdings board of directors in years:

1.8
Average Tenure
48.5
Average Age
  • The average tenure for the Choom Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Bogart

TITLE
CEO & Director
COMPENSATION
CA$130K
AGE
48
TENURE
13 yrs

Michael Forbes

TITLE
COO & Director
TENURE
1.3 yrs

Kevin Puil

TITLE
Director
AGE
46
TENURE
2.3 yrs

Stephen Stanley

TITLE
Member of Advisory Board
TENURE
7.6 yrs

Steven Tong

TITLE
Director
AGE
49
TENURE
3.6 yrs

John Oh

TITLE
Director
AGE
49
TENURE
1.8 yrs

Derek Chan

TITLE
Member of Advisory Board
TENURE
1.3 yrs

John Heaney

TITLE
Member of Advisory Board
TENURE
1.3 yrs

Bobby Black

TITLE
Member of Advisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Choom Holdings individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
17. Sep 19 Buy Christopher Bogart Individual 17. Sep 19 17. Sep 19 30,000 CA$0.39 CA$11,525
10. Sep 19 Buy Christopher Bogart Individual 04. Sep 19 09. Sep 19 20,000 CA$0.38 CA$7,569
04. Sep 19 Buy Christopher Bogart Individual 20. Aug 19 28. Aug 19 184,500 CA$0.40 CA$72,571
20. Aug 19 Buy Christopher Bogart Individual 19. Aug 19 19. Aug 19 24,500 CA$0.42 CA$9,950
16. Aug 19 Buy Christopher Bogart Individual 15. Aug 19 16. Aug 19 126,000 CA$0.42 CA$52,131
14. Aug 19 Buy Christopher Bogart Individual 14. Aug 19 14. Aug 19 20,000 CA$0.43 CA$8,425
26. Feb 19 Buy Christopher Bogart Individual 19. Feb 19 19. Feb 19 67,000 CA$0.47 CA$31,264
29. Jan 19 Buy Christopher Bogart Individual 22. Jan 19 29. Jan 19 115,000 CA$0.47 CA$51,423
12. Dec 18 Buy Christopher Bogart Individual 05. Dec 18 06. Dec 18 277,500 CA$0.45 CA$122,221
28. Nov 18 Buy Christopher Bogart Individual 07. Nov 18 27. Nov 18 230,000 CA$0.87 CA$152,762
20. Nov 18 Buy Stephen Tong Individual 19. Nov 18 19. Nov 18 25,000 CA$0.65 CA$16,250
X
Management checks
We assess Choom Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Choom Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Did Choom Holdings Inc's (CNSX:CHOO) CEO Pocket Last Year?

Chris Bogart took the helm as Choom Holdings Inc's (CNSX:CHOO) CEO and grew market cap to CA$152.26m recently. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … View out our latest analysis for Choom Holdings

Simply Wall St -

Company Info

Description

Choom Holdings Inc., through its subsidiary, Medi-Can Health Solutions Ltd, engages in cultivating and selling cannabis for medical purposes and related products. It operates cannabis stores in Niagara Falls, Ontario; and Medicine Hat, Alberta. The company was formerly known as Standard Graphite Corporation and changed its name to Choom Holdings Inc. in November 2017. Choom Holdings Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Details
Name: Choom Holdings Inc.
CHOO
Exchange: CNSX
Founded: 2006
CA$72,975,570
194,601,522
Website: http://www.choom.ca
Address: Choom Holdings Inc.
409 Granville Street,
Suite 350,
Vancouver,
British Columbia, V6C 1T2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CHOO Common Shares Canadian National Stock Exchange CA CAD 17. Dec 2007
OTCPK CHOO.F Common Shares Pink Sheets LLC US USD 17. Dec 2007
DB ORO Common Shares Deutsche Boerse AG DE EUR 17. Dec 2007
DB ORO COM NPV Deutsche Boerse AG DE EUR 24. Nov 2017
Number of employees
Current staff
Staff numbers
0
Choom Holdings employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/21 00:09
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/05/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.